FDA approval pathway propels Sangamo Therapeutics shares upward: what’s next?
Sangamo Therapeutics experienced a significant surge in its stock price, jumping by as much as 53%, after the U.S. Food and Drug Administration (FDA) indicated ... Read More
Sangamo, Prevail Therapeutics ink deal for evaluating AAV capsids
Sangamo Therapeutics, a genomic medicine company, has entered an evaluation and option agreement with Prevail Therapeutics, an Eli Lilly subsidiary, for novel engineered capsids. The ... Read More